EGFR Tyrosine Kinase Inhibitors Serine-Threonine Kinase Inhibitors CD Protein Inhibitors Immune Checkpoint Inhibitors Immunotherapy PARP Inhibitors Other PI3 Kinase Inhibitors Chemotherapy Heat Shock Protein Inhibitors Threonine-Tyrosine Kinase Inhibitors RAS Cyclin Dependent Kinase Inhibitors | Breast Cancer | Ovarian Cancer | HER2 Negative Breast Cancer | Cervical Cancer | Gastric Cancer | Hepatocellular Cancer | Hormone Receptor Positive Breast Cancer | Colorectal Cancer | Non Small Cell Lung Cancer | HER2 Positive Breast Cancer | Thyroid Gland Papillary Carcinoma | Squamous Cell Carcinoma of Head and Neck | Melanoma |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CYH33 | |||||||||||||
pembrolizumab | |||||||||||||
TAS-117 | |||||||||||||
olaparib + durvalumab + capivasertib | |||||||||||||
MK-2206 | |||||||||||||
RTB101 | |||||||||||||
BMS-722782 | |||||||||||||
trametinib | |||||||||||||
GDC-0941 | |||||||||||||
rigosertib | |||||||||||||
GDC-0032 | |||||||||||||
vemurafenib | |||||||||||||
alpelisib | |||||||||||||
abemaciclib + RLY-2608 | |||||||||||||
palbociclib + RLY-2608 | |||||||||||||
cetuximab | |||||||||||||
RLY-2608 | |||||||||||||
osimertinib | |||||||||||||
lapatinib | |||||||||||||
ado-trastuzumab emtansine | |||||||||||||
trastuzumab + lapatinib |